ALLIANCE A051701

Primary Category:

Treatment Protocols

Disease Category:

Diffuse Large B-cell Lymphoma, Lymphoma, Non-Hodgkin Lymphoma

Status:

Open

Randomized Phase II/III Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas

NCT#03984448

A051701 accrual of patients with double expressing lymphoma (DEL) will be temporarily halted effective August 2, 2021.

A051701 accrual of patients of all ages with double hit lymphoma (DHL) is temporarily halted effective September 28, 2020.